Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients - PubMed (original) (raw)
. 1999 Oct;180(4):1338-41.
doi: 10.1086/314988.
Affiliations
- PMID: 10479168
- DOI: 10.1086/314988
Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients
D N Forthal et al. J Infect Dis. 1999 Oct.
Abstract
The exact immune defects leading to human immunodeficiency virus (HIV)-associated opportunistic infections, malignancies, and death are unknown. In this study, the relationship between survival and 2 immune functions, cytomegalovirus-specific antibody-dependent cellular cytotoxicity (ADCC) and natural killer (NK) activity, was determined by using peripheral blood mononuclear cells from 39 severely immunocompromised patients (median CD4 count, 7). Median follow-up was 414 days; 15 subjects died and 24 remained alive. In a Kaplan-Meier analysis, high baseline ADCC (>median) was associated with improved survival (P=.05). A similar trend was observed for NK activity (P=.1). In a multivariate model controlling for baseline CD4 cell count, HIV RNA, and use of protease inhibitors during follow-up, high ADCC, but not high NK activity, remained significantly associated with a lower risk of death (relative risk, 0.18; 95% confidence interval, 0.05-0.75). ADCC may be an important determinant of disease progression independently of anti-retroviral therapy, CD4 cell count, and HIV RNA.
Similar articles
- Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).
Erice A, Tierney C, Hirsch M, Caliendo AM, Weinberg A, Kendall MA, Polsky B; AIDS Clinical Trials Group Protocol 360 Study Team. Erice A, et al. Clin Infect Dis. 2003 Aug 15;37(4):567-78. doi: 10.1086/375843. Epub 2003 Jul 29. Clin Infect Dis. 2003. PMID: 12905142 - Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease.
Bronke C, Palmer NM, Jansen CA, Westerlaken GH, Polstra AM, Reiss P, Bakker M, Miedema F, Tesselaar K, van Baarle D. Bronke C, et al. J Infect Dis. 2005 Mar 15;191(6):873-80. doi: 10.1086/427828. Epub 2005 Jan 31. J Infect Dis. 2005. PMID: 15717261 - Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis.
Komanduri KV, Feinberg J, Hutchins RK, Frame RD, Schmidt DK, Viswanathan MN, Lalezari JP, McCune JM. Komanduri KV, et al. J Infect Dis. 2001 Apr 15;183(8):1285-9. doi: 10.1086/319683. Epub 2001 Mar 12. J Infect Dis. 2001. PMID: 11262214 - Usefulness of the cytomegalovirus (CMV) antigenemia assay for predicting the occurrence of CMV disease and death in patients with AIDS.
Chevret S, Scieux C, Garrait V, Dahel L, Morinet F, Modaï J, Decazes JM, Molina JM. Chevret S, et al. Clin Infect Dis. 1999 Apr;28(4):758-63. doi: 10.1086/515188. Clin Infect Dis. 1999. PMID: 10825035 - The importance of cytotoxic cellular immunity in the protection from cytomegalovirus infection.
Quinnan GV Jr, Rook AH. Quinnan GV Jr, et al. Birth Defects Orig Artic Ser. 1984;20(1):245-61. Birth Defects Orig Artic Ser. 1984. PMID: 6329365 Review. No abstract available.
Cited by
- Impact of HIV-1 Vpu-mediated downregulation of CD48 on NK-cell-mediated antibody-dependent cellular cytotoxicity.
Marchitto L, Benlarbi M, Prévost J, Laumaea A, Descôteaux-Dinelle J, Medjahed H, Bourassa C, Gendron-Lepage G, Kirchhoff F, Sauter D, Hahn BH, Finzi A, Richard J. Marchitto L, et al. mBio. 2023 Aug 31;14(4):e0078923. doi: 10.1128/mbio.00789-23. Epub 2023 Jul 5. mBio. 2023. PMID: 37404017 Free PMC article. - Antibody-dependent cellular cytotoxicity, infected cell binding and neutralization by antibodies to the SIV envelope glycoprotein.
Grunst MW, Ladd RA, Clark NM, Gil HM, Klenchin VA, Mason R, Franchini G, Roederer M, Evans DT. Grunst MW, et al. PLoS Pathog. 2023 May 30;19(5):e1011407. doi: 10.1371/journal.ppat.1011407. eCollection 2023 May. PLoS Pathog. 2023. PMID: 37253062 Free PMC article. - HIV-gp140-Specific Antibodies Generated From Indian Long-Term Non-Progressors Mediate Potent ADCC Activity and Effectively Lyse Reactivated HIV Reservoir.
Dhande JR, Bagul RD, Thakar MR. Dhande JR, et al. Front Immunol. 2022 Mar 2;13:844610. doi: 10.3389/fimmu.2022.844610. eCollection 2022. Front Immunol. 2022. PMID: 35309295 Free PMC article. - Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features.
Cheng HD, Dowell KG, Bailey-Kellogg C, Goods BA, Love JC, Ferrari G, Alter G, Gach J, Forthal DN, Lewis GK, Greene K, Gao H, Montefiori DC, Ackerman ME. Cheng HD, et al. Retrovirology. 2021 Oct 30;18(1):35. doi: 10.1186/s12977-021-00579-9. Retrovirology. 2021. PMID: 34717659 Free PMC article. - Production of HIV-1 Env-specific antibodies mediating innate immune functions depends on cognate IL-21- secreting CD4+ T cells.
Pušnik J, Fischinger S, Dittmer U, Esser S, van Gils MJ, Sanders RW, Alter G, Streeck H. Pušnik J, et al. J Virol. 2021 Mar 25;95(8):e02097-20. doi: 10.1128/JVI.02097-20. Epub 2021 Jan 27. J Virol. 2021. PMID: 33504598 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials